Pharma Equity Group A/S Class A

As of June 30, 2025, Pharma Equity Group A/S Class A carries a market capitalization of 149.76M, placing it among publicly traded companies globally. Its enterprise value stands at 167.51M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2025, Pharma Equity Group A/S Class A has 1.23B shares outstanding.

These figures are as of June 30, 2025.

As of June 30, 2025, Pharma Equity Group A/S Class A maintains a current ratio of 8.02, meaning it holds 8.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2025, Pharma Equity Group A/S Class A recorded an income tax benefit of -1.20M rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on October 22, 2026, Pharma Equity Group A/S Class A's stock has declined approximately 25.63% over the past 52 weeks. The 50-day moving average sits at 0.08, while the 200-day moving average is 0.09.

As of June 30, 2025, Pharma Equity Group A/S Class A holds 702,000.00 in cash and equivalents against 18.45M in total debt, resulting in a net debt position of 17.63M. Total book value stands at 39.38M, with working capital of 53.97M providing operational flexibility.

Pharma Equity Group A/S Class A's most recent stock split took place on January 27, 2023 with a 1:2 split ratio.